MDT

99.02

+1.44%↑

146.01

+0.06%↑

VEEV

218.99

-0.4%↓

HQY

89.13

+4.04%↑

NEOG

9.46

+2.94%↑

MDT

99.02

+1.44%↑

146.01

+0.06%↑

VEEV

218.99

-0.4%↓

HQY

89.13

+4.04%↑

NEOG

9.46

+2.94%↑

MDT

99.02

+1.44%↑

146.01

+0.06%↑

VEEV

218.99

-0.4%↓

HQY

89.13

+4.04%↑

NEOG

9.46

+2.94%↑

MDT

99.02

+1.44%↑

146.01

+0.06%↑

VEEV

218.99

-0.4%↓

HQY

89.13

+4.04%↑

NEOG

9.46

+2.94%↑

MDT

99.02

+1.44%↑

146.01

+0.06%↑

VEEV

218.99

-0.4%↓

HQY

89.13

+4.04%↑

NEOG

9.46

+2.94%↑

Kodu・Aktsiate loetelu・Lisata Therapeutics

L
Lisata Therapeutics

Avatud

2.16 6.4

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.03

Max

2.15

Põhinäitajad
By Trading Economics
Töötajad	26

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	26. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	-4.6M 16M
Eelmine avamishind	-4.24
Eelmine sulgemishind	2.16

Lisata Therapeutics Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. jaan 2026, 22:41 UTC

Omandamised, ülevõtmised, äriostud

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15. jaan 2026, 00:00 UTC

Tulu

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14. jaan 2026, 23:47 UTC

Market Talk

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14. jaan 2026, 23:44 UTC

Market Talk

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14. jaan 2026, 23:39 UTC

Market Talk

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14. jaan 2026, 23:32 UTC

Market Talk

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14. jaan 2026, 22:56 UTC

Omandamised, ülevõtmised, äriostud

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14. jaan 2026, 22:53 UTC

Omandamised, ülevõtmised, äriostud

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14. jaan 2026, 22:17 UTC

Market Talk

Global Equities Roundup: Market Talk

14. jaan 2026, 22:17 UTC

Market Talk

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14. jaan 2026, 22:09 UTC

Tulu

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14. jaan 2026, 22:08 UTC

Tulu

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14. jaan 2026, 22:08 UTC

Tulu

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14. jaan 2026, 21:53 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14. jaan 2026, 21:53 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14. jaan 2026, 21:52 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC Announces Positive Profit Alert for 2025

14. jaan 2026, 21:51 UTC

Omandamised, ülevõtmised, äriostud

Citigroup Acting as Financial Advisor to WuXi XDC

14. jaan 2026, 21:51 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC: Aims to Keep Listing Status of BioDlink

14. jaan 2026, 21:51 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14. jaan 2026, 21:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

14. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14. jaan 2026, 21:49 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14. jaan 2026, 21:48 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14. jaan 2026, 21:48 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC Makes Cash Offer for BioDlink International

14. jaan 2026, 21:13 UTC

Market Talk

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14. jaan 2026, 20:30 UTC

Market Talk

Tulu

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14. jaan 2026, 20:13 UTC

Market Talk

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14. jaan 2026, 20:08 UTC

Market Talk

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14. jaan 2026, 19:33 UTC

Market Talk

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14. jaan 2026, 19:06 UTC

Market Talk

Tulu

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Lisata Therapeutics Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Lisata Therapeutics aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Ettevõttest Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.